2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19858
    LY-466195 317844-33-0 98%
    LY-466195 is a selective and competitive GLUK5 receptor antagonist. LY-466195 antagonizes Kainate-induced currents with an IC50 value of 0.045 μM in rat dorsal root ganglion neurons. In HEK293 cells transfected with GLUK5, GLUK2/GLUK5, or GLUK5/GLUK66 receptors, LY466195 produces IC50 values of 0.08 μM, 0.34 μM, and 0.07 μM, respectively.
    LY-466195
  • HY-19875
    Seridopidine 883631-51-4 98%
    Seridopidine is an orally active dopamine-like compound. Seridopidine can be used in research related to the nervous system.
    Seridopidine
  • HY-19881
    ABT-288 948845-91-8 98%
    ABT-288 is a competitive, potent and selective histamine H3 receptor (H3R) antagonist. ABT-288 has Ki values of 1.9 and 8.2 nM for human and rat H3Rs, respectively. ABT-288 can be used in cognitive impairment research..
    ABT-288
  • HY-19887
    Tilapertin 1000690-85-6 98%
    Tilapertin is an oral inhibitor of glycine transporter type-1 (GlyT1).
    Tilapertin
  • HY-19902
    GSK1521498 1426543-84-1 98%
    GSK1521498 is a potent and selective μ-opioid receptor (MOR) antagonist. GSK1521498 has the potential for disorders of compulsive consumption of food, alcohol, and agents.
    GSK1521498
  • HY-19950
    5-HT2A receptor agonist-6 1028307-48-3 98%
    5-HT2A receptor agonist-6 (compound 47) is a selective 5-HT2A receptor agonist (pEC50=6.58).
    5-HT2A receptor agonist-6
  • HY-19999
    PF-CBP1 1962928-21-7 98%
    PF-CBP1 is a highly selective inhibitor of the CREB binding protein bromodomain.
    PF-CBP1
  • HY-21994
    Org-12962 hydrochloride 210821-63-9 98%
    Org 12962 hydrochloride is a potent, selective and efficacious 5-HT2C receptor agonist and exhibits pEC50 values of 7.01, 6.38 and 6.28 for 5-HT2C, 5-HT2A and 5-HT2A, respectively. Org 12962 hydrochloride is effective in panic-like anxiety animal model.
    Org-12962 hydrochloride
  • HY-21995
    BGC20-761 17375-63-2 98%
    BGC20-761 is a selecvtive 5-HT6 and dopamine receptor antagonist (human receptor Ki values: 5-HT6 (20 nM), 5-HT2A (69 nM), D2 (140 nM). BGC20-761, can enhance long-term memory. BGC20-761 has potential utility as an antipsychotic agent.
    BGC20-761
  • HY-41240
    (R)-3-Aminoazepan-2-one 28957-33-7 98%
    (R)-3-Aminoazepan-2-one (compound 9B) is a synthetic intermediate useful for pharmaceutical synthesis.
    (R)-3-Aminoazepan-2-one
  • HY-42649
    NSC 14699 2513-33-9 99.64%
    NSC 14699 is a small molecule non-peptide inhibitor of botulinum neurotoxin serotype E. NSC 14699 is promising for research of therapeutic and cosmetic agents.
    NSC 14699
  • HY-42849
    Sultopride 53583-79-2 98%
    Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor.
    Sultopride
  • HY-43711
    Nor-benzetimide 19315-71-0 98%
    Nor-benzetimide is a major metabolite of Benzetimide. Benzetimide is a mAChR antagonist with anticholinergic activity.
    Nor-benzetimide
  • HY-44132
    Dehydro Palonosetron 135729-56-5 98%
    Dehydro Palonosetron (RS 42358-197) is a potent, seslective and orally active 5-HT3 receptor antagonist. Dehydro Palonosetron has no effect on the activities of 5-HT1 receptors, 5-HT2 receptors or 5-HT4 receptors.
    Dehydro Palonosetron
  • HY-48869
    PI3K-IN-46 304645-61-2 ≥98.0%
    PI3K-IN-46 (Intermediate 4) is an intermediate in the synthesis of PI3K inhibitor (2-imino-azolinone-vinyl fused-benzene derivative) that can be used for the research of autoimmune disorders, cardiovascular diseases, and neurodegenerative diseases.
    PI3K-IN-46
  • HY-49066
    Sodium Channel inhibitor 4 587843-16-1 ≥98.0%
    Sodium Channel inhibitor 4 is a sodium channel inhibitor.
    Sodium Channel inhibitor 4
  • HY-49373
    AChE-IN-64 148305-62-8 98%
    AChE-IN-64 (compound C4) is an AChE inhibitor (IC50: 36.9 µM), and can be used for cognitive disorders research.
    AChE-IN-64
  • HY-49463
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz is an ADC linker that can be used in the synthesis of ADCs (such as Trastuzumab deruxtecan and U3-1402).
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz
  • HY-50884
    BMS 433796 935525-13-6 98%
    BMS 433796 is a γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer's disease.
    BMS 433796
  • HY-50892
    (Rac)-Roscovitine 186692-44-4 98%
    (Rac)-Roscovitine ((Rac)-Seliciclib) is a selective cyclin-dependent kinases (CDKs) inhibitor. (Rac)-Roscovitine binds to the active sites of CDKs competitively with ATP, inhibiting the phosphorylation activity of CDKs. (Rac)-Roscovitine induces apoptosis in cancer cells. (Rac)-Roscovitine is promising for research of cancers or other diseases associated with CDK dysregulation, such as neurodegenerative diseases, cardiac disorders, viral and protozoan infections, glomerulonephritis, and chronic inflammation.
    (Rac)-Roscovitine
Cat. No. Product Name / Synonyms Application Reactivity